💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Loratadine

CHEMBL998 Phase 4 Aprobado Small molecule
Half-Life
8 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
382.9 g/mol
LogP
5.2
Phase
4

A second-generation, non-sedating antihistamine, loratadine blocks peripheral H1 histamine receptors to reduce sneezing, runny nose, and itching without causing significant drowsiness. It treats allergic rhinitis and chronic hives. Sold over the counter as Claritin and Alavert, the compound has the formula C22H23ClN2O2 and its minimal central nervous system penetration distinguishes it from older allergy medications.

A second-generation, non-sedating antihistamine used to relieve allergic rhinitis and hives (urticaria). It blocks peripheral H1 histamine receptors to reduce sneezing, runny nose, and itching without causing significant drowsiness.

Peso molecular

382,8800 g/mol

LogP

5,20

TPSA

42,40 Ų

Regla de cinco de Lipinski

Cumple

Clases de fármacos

R — R - Sistema respiratorio

Mecanismo de acción

Second-generation H1 antihistamine with minimal CNS effects.

Pharmacokinetics (PK)

Half-Life 8 hours

Pharmacodynamics (PD)

Mecanismo

Second-generation H1 antihistamine with minimal CNS effects.

Estructura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1

                

                

                
                

                    
InChI

                    
InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H23ClN2O2

                    

                    
                    

                        
HBD / HBA

                        
- / 3

                    

                    
                    

                        
Enlaces Rotables

                        
2

                    

                    
                    
                    

                        
Átomos Pesados

                        
27

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            HRH1 (Receptor de histamina H1)
                            Antagonist
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Minor


                            
                                Loratadine + Fluconazole
                            
                        

                        
                        
Fluconazole inhibits CYP3A4-mediated metabolism of loratadine, modestly increasing loratadine plasma concentrations; however, loratadine's poor CNS penetration limits the clinical consequence.

                        
                    
                    
                    
                        

                            

  
  Minor


                            
                                Loratadine + Azithromycin
                            
                        

                        
                        
Azithromycin is a weak CYP3A4 inhibitor that can modestly raise loratadine plasma levels; the clinical impact is minimal given loratadine's wide therapeutic index and low cardiac risk.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Preguntas frecuentes

                

                    
                    

                        
                        

                            
A second-generation, non-sedating antihistamine used to relieve allergic rhinitis and hives (urticaria). It blocks peripheral H1 histamine receptors to reduce sneezing, runny nose, and itching without causing significant drowsiness.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Second-generation H1 antihistamine with minimal CNS effects.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Loratadine: Half-life: 8 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Loratadine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Albuterol
                            Small molecule
                        
                        
                        
                            Montelukast
                            Small molecule
                        
                        
                        
                            Cetirizine
                            Small molecule
                        
                        
                        
                            Diphenhydramine
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL998.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 3957.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Aviso médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.